Merck Emerging Markets President Kevin Ali On The Branded Generics Business: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
When Merck & Co. Inc. Emerging Markets President Kevin Ali speaks of innovation, it is emblematic of Merck's deep-rooted focus on new drug discovery, but the veteran executive now sees opportunities in the differentiated, branded generics segment. On a recent visit to India, Ali spoke to PharmAsia News' India Bureau about incrementally innovative drugs, access to affordable medicines and also Merck's plans in the BRIC-MT nations.
You may also be interested in...
Merck’s ‘Three Pillars’ Strategy Takes Big Step With New Hangzhou Plant
Merck President of Global Human Health Adam Schechter talks about the company’s strategy in China and emerging markets following the opening of Merck’s $120 million plant in Hangzhou, China.
Merck’s ‘Three Pillars’ Strategy Takes Big Step With New Hangzhou Plant
Merck President of Global Human Health Adam Schechter talks about the company’s strategy in China and emerging markets following the opening of Merck’s $120 million plant in Hangzhou, China.
Emerging Markets Earnings Roundup: Bayer And Merck (Part 3)
Emerging markets were a mixed picture for Big Pharma in the third quarter, with China the clear leader, but overall key markets continued to see slower growth, which many blamed on the slowdown in the West.